(135) Systematic Review on the Association of Peyronie’s Disease Development and Severity to Testosterone Level: Do we Have Enough Data?

Abstract Introduction Exact pathophysiology of Peyronie's disease (PD) are still poorly known with the combination of tissue ischemia to predefined hereditary variables. Due to the anti-inflammatory factors and ability to regulate collagen metabolism and wound healing, androgens have been the subject of several clinical research studying their role in the onset and severity of PD. Objective The aim of this study is to investigate the relationship between testosterone level to the development and severity of PD. Methods A systematic search on PubMed, Scopus, and Embase was conducted on April 4th, 2023 using the keywords of testosterone, hypogonadism, and Peyronie’s disease. All studies that compare the testosterone levels of the patients with or without PD or evaluate the association of PD severity were considered. Each included studies are evaluated for its quality and risk of bias. Results Eleven studies comprising 1.106 patients with PD and 507 control were included. Three of the four studies examining the association of testosterone level to PD development found that testosterone/DHEA-s levels were lower in the PD group compared to the control. In addition, four of seven studies found that the severity or degree of penile curvature among patients with PD has lower testosterone levels. On contrary, only two of six studies support the correlation of testosterone level to penile plaque diameter. In two studies that confirmed the correlation of penile plaque and degree of curvature to testosterone levels, they also found that PD patients with normal or higher testosterone levels responds better to medical treatment. Conclusions Contemporary literature on the correlation between PD and testosterone levels shows conflicting results. Although around half of the studies support its possible correlation to penile curvature severity, no definitive conclusion can be made. Further research is warranted to seek the impact of low testosterone level to PD and whether it needs to be routinely evaluated in clinical practice. Disclosure No.